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Abstract. Feral monk parakeet (Myiopsitta monachus) populations have become established in the United States and
other countries around the world, and can cause damage to electrical facilities. Because the monk parakeet is a highly
visible species and there is often public opposition to lethal control measures, non-lethal methods, such as contraception,
are being developed to help control the spread of feral populations. Two gavage studies and one ad libitum nesting study
were conducted to assess the efficacy of DiazaCon™ as a potential contraceptive for the monk parakeet. The first gavage
study compared daily dose levels of 0, 50, 75, and 100 mg DiazaCon™ (kg bodyweight)–1 administered for 10 consecutive days. Cholesterol concentrations decreased significantly concomitant with a significant increase in desmosterol
concentrations in the treated groups, but did not vary between sexes. Cholesterol and desmosterol concentrations did not
differ significantly among DiazaCon™ groups, and cholesterol remained significantly suppressed 12 weeks after treatment. On the basis of these results, the second gavage study compared 5 or 10 consecutive days of DiazaCon™ administration at 50 mg kg–1 bird–1 day–1. Cholesterol concentrations decreased significantly concomitant with a significant
increase in desmosterol concentrations in the treated groups, but did not vary between sexes. Cholesterol and desmosterol
concentrations did not differ significantly between DiazaCon™ groups, and cholesterol remained significantly suppressed
11 weeks after treatment. Parakeets in the nesting study were fed hulled sunflower seeds treated with a target dose of
50 mg DiazaCon™ kg–1 bird–1 day–1. Birds consumed enough to receive an average dose of 34 mg kg–1 pair–1 day–1, or
17 mg kg–1 bird–1 day–1. Birds in the treated group laid an average of 1.6 ± 0.7 eggs per clutch compared with 3.9 ± 1.1
eggs per clutch in the untreated control group. None of the eggs laid by treated birds hatched compared with 1.1 ± 0.6 eggs
per clutch hatching in the control group. Reproductive inhibition was effective for the length of the breeding season, at
which time the study was stopped and no more data were collected. DiazaCon™ is a promising avian oral contraceptive
that should be further investigated in a field setting with monk parakeets.

Introduction
The monk parakeet (Myiopsitta monachus) is a parrot whose
native range extends from central Bolivia and southern Brazil to
central Argentina. Highly adaptable, the species has become
established in the United States as well as in Puerto Rico, the
Bahamas, the West Indies, Belgium, Italy, Spain and the Canary
Islands (Spreyer and Bucher 1998). Monk parakeets became
established in New York in the United States in the 1960s
through a combination of intentional and accidental releases.
Concerned about the potential damage this introduced species
might cause, the United States Fish and Wildlife Service implemented a removal program in the 1970s (Neidermyer and
Hickey 1977). The program reduced the population by 44% and
ended in 1975. Since then, monk parakeet populations in the
United States have grown dramatically, with populations in
Florida growing exponentially over the last 30 years (van Bael
and Pruett-Jones 1996; Pruett-Jones et al. 2005).
Although the monk parakeet is considered an agricultural
pest in South America, it has so far been associated with little
agricultural damage in the United States (Bump 1971; Bucher
© CSIRO 2007

and Bedano 1976; Pruett-Jones and Tarvin 1998; Tillman et al.
2001). However, the monk parakeet causes substantial damage
by its nest-building activities. The monk parakeet is the only
parrot species to construct its own nest, which is a large, bulky
structure of sticks and branches used both for breeding and
roosting. Many of the nest structures are built in electric utility
substations and on support structures for distribution and transmission lines (Bucher and Martín 1987; Marone et al. 1992; van
Doorn 1997; Avery et al. 2002; Tillman et al. 2004). Nesting
materials can cause short circuits directly by arcing power structures, and other outages occur when parakeets, or predators
attracted by parakeet nesting activity, are electrocuted. In
Florida, problems with monk parakeets at electric power facilities have occurred at least since the late 1980s, and the species
also adversely affects the reliability of electrical services in
other states, including New York, Connecticut and Texas (Avery
et al. 2002, 2006).
Various methods of control have been used in South America
and the United States, including shooting, fire, netting and
10.1071/WR06069
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poison. These methods were largely unsuccessful in South
America (Godoy 1963), and meet with public opposition in the
United States. A publicly acceptable method of control is reproductive inhibition (Messmer et al. 1997; Stout et al. 1997).
Monk parakeets can lay 4–12 eggs per clutch, with 6 eggs per
clutch the average size (Navarro et al. 1992; Peris and Aramburu
1995; Spreyer and Bucher 1998). Any significant reduction in
reproductive rate will likely affect population growth. Monk
parakeets are an ideal species for control through reproductive
inhibition as they have low dispersal rates (Martín and Bucher
1993; Spreyer and Bucher 1998), and they frequent bird feeders
that potentially can be used to deliver a reproductive inhibitor.
One promising contraceptive is 20,25-diazacholesterol
dihydrochloride (DiazaCon™) which prevents the conversion
of desmosterol to cholesterol by inhibiting the Δ24-reductase
enzyme (Emmons et al. 1982; Yoder et al. 2004). DiazaCon™
was formerly registered in the United States under the trade
name Ornitrol to control reproduction of feral pigeons.
Cholesterol is needed for the production of pregnenolone, the
precursor hormone to progesterone, oestradiol and testosterone.
Progesterone and oestradiol are needed for egg formation, ovulation and egg-laying; testosterone is necessary for sperm production. Reducing cholesterol reduces reproductive steroid
hormone synthesis, thereby decreasing reproduction (Yoder
et al. 2004).
Two gavage studies and a nesting study were undertaken to
determine the efficacy of DiazaCon™ as a contraceptive for the
monk parakeet. The purpose of the two gavage studies was to
determine a minimum effective dose and the minimum length of
time DiazaCon™ can be applied without reducing efficacy. The
purpose of the nesting study was to quantify the effect of
DiazaCon™ on egg production and hatchability in captive birds
under free-feeding conditions. All experimental protocols were
reviewed and approved by the National Wildlife Research
Center’s (NWRC) Animal Care and Use Committee, and complied with the Animal Welfare Act.
Materials and methods
All birds were trapped in southern Florida and transported to the
NWRC field station in Gainesville, Florida, for testing.
Parakeets were banded, weighed, and housed in groups of 10–12
in outdoor pens (9.3 × 3.1 × 1.8 m) for a minimum of six months
before testing. Blood was obtained from the brachial vein for
DNA analysis to determine the sex of each bird (Griffiths et al.
1998). Parakeets were maintained on a diet of mixed seeds,
fresh fruit and lettuce.
Dose–response gavage study
Parakeets were randomly assigned to one of four treatment
groups (n = 10 per group): (1) 0 mg kg–1, (2) 50 mg kg–1,
(3) 75 mg kg–1, or (4) 100 mg kg–1. One male and one female
parakeet were transferred to individual cages (45 × 45 × 45 cm)
in a roofed outdoor aviary for testing. Pairs were allowed to
acclimate for ≥3 weeks before treatment. DiazaCon™ was dissolved in water such that each bird received the appropriate
amount of DiazaCon™ in 1 mL of water. Control birds were
gavaged with water only. Birds were gavaged once a day for
10 consecutive days using a rounded 20-gauge stainless steel
gavage needle.
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Blood (1 mL) was drawn from the jugular vein on Days 0, 7,
14, 28, 42, 70 and 98, and birds were weighed at the time of
blood collection. Plasma was analysed for desmosterol and
cholesterol concentrations by high-performance liquid chromatography (HPLC) using the method of Johnston et al. (2003).
At the end of the study, birds were euthanised, and the testes and
ovaries were removed and weighed (wet weight). Only testes
from the control and 100 mg kg–1 groups were weighed.
Exposure period gavage study
Parakeets were randomly assigned to one of three treatment
groups (n = 10 per group): (1) 0 mg kg–1, (2) 50 mg kg–1 for five
consecutive days, or (3) 50 mg kg–1 for 10 consecutive days. For
testing, parakeets were transferred from the communal pen to
individual cages (45 × 45 × 45 cm) in a roofed outdoor aviary.
DiazaCon™ was dissolved in water such that each bird received
the appropriate amount of DiazaCon™ in 1 mL of water. Birds
were gavaged once a day according to the treatment group to
which they were assigned using a rounded 20-gauge stainless
steel gavage needle. Control birds were gavaged once a day for
10 consecutive days with water only.
Blood (1 mL) was drawn from the jugular vein on Days 0, 7,
14, 21 and 77, and each bird was weighed at the time of blood
collection. Plasma was analysed by HPLC for desmosterol and
cholesterol concentrations (Johnston et al. 2003). A small
portion of the pretreatment blood sample was used for DNA
analysis to determine the sex of each bird (Griffiths et al. 1998).
Nesting study
Pairs were housed in groups of 10–12 in outdoor pens (9.3 × 3.1
× 1.8 m), and we identified pairs of birds based on their propensity to perch near one another and allopreen. Pairs were randomly assigned to either a control group or a DiazaCon™ group
and transferred from the communal pens to individual cages
(1.8 × 1.2 × 1.2 m) in a roofed outdoor aviary for testing. Each
cage had a nesting platform (30 × 30 cm), and short sticks and
branches were supplied ad libitum as nesting material. Pairs
were allowed to acclimate for ≥3 weeks before treatment.
Bait was prepared by dissolving DiazaCon™ in water,
mixing the solution with hulled sunflower seeds, and allowing
the mixture to dry overnight. The final mixture of seeds contained 0.05% DiazaCon™ (w/w). The target dose was 50 mg
kg–1 and was based on each bird weighing 110 g, on average,
and consuming 11 g of seed per day. Each pair was offered 30 g
of sunflower seeds for five consecutive days. Seed was placed in
a small food cup, which was placed on a larger pan to facilitate
weighing back of uneaten seed to determine consumption and to
estimate the actual dose of DiazaCon™ received.
Nest building and nest status were observed daily until the
first egg was laid. Thereafter, nests were checked weekly to
determine the number of eggs laid and/or hatched. The study
was terminated in mid-August when it was determined that the
birds were no longer reproducing.
Statistical analysis
All data except egg production, number of chicks hatched, and
gonad weights were analysed as a mixed-effects model (PROC
MIXED: SAS Institute Inc. 2003). Data were analysed for treatment, week, and treatment-by-week interaction effects. Where
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appropriate, data were also analysed for differences between
sexes. Egg production, number of chicks hatched, and gonad
weights were analysed using Wilcoxon’s rank sum test.

0 mg/kg

50 mg/kg

100 mg/kg

75 mg/kg

600
400 Treatment
began
200
POST12

POST10

POST8

POST4

POST2

TRT2

TRT1

PRE

0

Treatment week

Fig. 1. Desmosterol concentrations in plasma of monk parakeets
(Myiopsitta monachus) treated with either 0, 50, 75 or 100 mg DiazaCon™
(kg bodyweight)–1 once per day for 10 days. Error bars represent the standard error of the mean.
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Fig. 2. Cholesterol concentrations in plasma of monk parakeets
(Myiopsitta monachus) treated with either 0, 50, 75 or 100 mg DiazaCon™
(kg bodyweight)–1 once per day for 10 days. Error bars represent the standard error of the mean.

Exposure period gavage study
Desmosterol and cholesterol concentrations varied by treatment
(P < 0.0001 and 0.0032, respectively) and week (P < 0.0001),
and there was a significant treatment-by-week interaction
(P < 0.0001). Desmosterol concentrations increased (Fig. 3),
and cholesterol concentrations decreased (Fig. 4) in the treated
groups compared with the control group. Cholesterol concentrations remained suppressed 11 weeks after treatment. There
was no difference between DiazaCon™ groups with respect to
cholesterol suppression. Desmosterol and cholesterol concentrations did not vary between sexes (P = 0.9394 and 0.9119,
respectively). The overall means of desmosterol concentrations,
excluding the pretreatment period, were 5.0 ± 1.9 (n = 40), 542.8
± 42.6 (n = 37) and 535.0 ± 59.5 (n = 36) µg mL–1 in the control,
5-day and 10-day treatment groups, respectively. The overall
means of cholesterol concentrations, excluding the pretreatment
period, were 867.4 ± 37.9 (n = 40), 542.3 ± 41.9 (n = 37) and
508.4 ± 43.8 (n = 36) µg mL–1 in the control, 5-day and 10-day
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Results
Dose–response gavage study
Desmosterol and cholesterol concentrations varied by treatment
(P < 0.0001) and week (P < 0.0001), and there was a significant
treatment-by-week interaction (P < 0.0001). Desmosterol
concentrations increased (Fig. 1), and cholesterol concentrations decreased (Fig. 2) in the treated groups compared with
the control group. Cholesterol concentrations remained
markedly suppressed 12 weeks after treatment. There were no
differences among DiazaCon™ groups with respect to cholesterol suppression. Desmosterol and cholesterol concentrations
did not vary between sexes (P = 0.3513 and 0.5998, respectively). The overall means of desmosterol concentrations,
excluding the pretreatment period, were 21.4 ± 6.4 (mean ±
s.e.m; n = 60), 739.5 ± 68.5 (n = 51), 637.0 ± 56.7 (n = 47) and
703.8 ± 45.3 (n = 55) µg mL–1 in the 0, 50, 75 and 100 mg kg–1
groups, respectively. The overall means of cholesterol concentrations, excluding the pretreatment period, were 809.7 ± 45.3
(n = 60), 328.0 ± 32.6 (n = 51), 371.7 ± 42.7 (n = 47) and
310.5 ± 36.8 (n = 55) µg mL–1 in the 0, 50, 75 and 100 mg kg–1
groups, respectively.
Testicular and ovarian weights did not vary by treatment
(P = 0.4498 and 0.2385, respectively). Mean testicular weights
were 0.03 ± 0.01 g in both the control and 100 mg kg–1 treatment
group (n = 6 and 3, respectively). Mean ovarian weights were 0.05
± 0.02 (n = 3), 0.08 ± 0.01 (n = 5), 0.08 ± 0.00 (n = 2) and 0.06 ±
0.01 g (n = 6) in the 0, 50, 75 and 100 mg kg–1 groups, respectively. During the study, a total of 10 birds died (all males); four
birds died in both the 50 mg kg–1 and 75 mg kg–1 groups, and two
birds died in the 100 mg kg–1 group. One male in the 75 mg kg–1
group died on Day 10 of dosing, likely a result of aspiration of the
gavage material. The remainder of the birds died 10–34 days after
treatment. No mortality was observed in the control group.
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Fig. 3. Desmosterol concentrations in plasma of monk parakeets
(Myiopsitta monachus) treated with 50 mg DiazaCon™ (kg bodyweight)–1
for 5 or 10 consecutive days, or 0 mg DiazaCon™ (kg bodyweight)–1 for 10
consecutive days. Error bars represent the standard error of the mean.
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Fig. 4. Cholesterol concentrations in plasma of monk parakeets
(Myiopsitta monachus) treated with 50 mg DiazaCon™ (kg bodyweight)–1
for 5 or 10 consecutive days, or 0 mg DiazaCon™ (kg bodyweight)–1 for 10
consecutive days. Error bars represent the standard error of the mean.

treatment groups, respectively. During the trial, three birds
(two males, one female) died in each of the treatment groups
≥14 days after treatment, whereas no mortality was observed in
the control group. Parakeets in the 5-day treatment group died
26–42 days after treatment, whereas birds in the 10-day treatment group died 14–28 days after treatment.
Nesting study
No eggs hatched in the treated group (n = 10 clutches) compared
with 1.1 ± 0.6 eggs per clutch (n = 10 clutches) in the control
group (P = 0.0470). Control birds averaged 3.9 ± 1.1 eggs per
clutch (n = 10 clutches) compared with 1.6 ± 0.7 eggs per clutch
(n = 10 clutches) for treated birds (P = 0.0644). The amount of
seed consumed varied among days (P < 0.0001), but not
between groups (P = 0.2794). Feed consumption was lowest on
the first day, averaging 11.0 ± 1.0 g per pair (n = 20), compared
with 17.0 ± 0.9 g per pair (n = 80) on the remaining four days.
The average daily DiazaCon™ dose per pair was 33.7 ± 2.2 mg
(kg bodyweight)–1 (n = 50), or 16.8 ± 1.1 mg (kg bodyweight)–1
bodyweight per bird. The average daily dose was calculated
based on food consumption per pair and an assumed average
pair weight of 220 g. No birds died during the nesting trial.
Discussion
In the first gavage trial, DiazaCon™ decreased plasma cholesterol concentrations ~50% by the second week of treatment in
all treatment groups. Cholesterol was still suppressed ≥50% at
12 weeks after treatment, although plasma concentrations were
beginning to increase. Desmosterol concentrations remained
elevated and did not appear to be decreasing at 12 weeks after
treatment. These results show DiazaCon™ can suppress
cholesterol for the length of a breeding season, thereby reducing reproduction.
In the second gavage trial, DiazaCon™ decreased plasma
cholesterol concentrations by 67% in both treatment groups by
the third week after treatment. By 11 weeks after treatment,
cholesterol concentrations were still suppressed by 60% in the
group receiving DiazaCon™ for 10 days, compared with 44%
in the group receiving DiazaCon™ for 5 days. Desmosterol
concentrations were decreasing by 11 weeks after treatment in
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both treatment groups. These results indicate that feeding
DiazaCon™ for 5–10 days reduces plasma cholesterol sufficiently to affect reproduction for the length of a breeding
season, and that the effects are reversible.
These results are consistent with the results of a previous
study (Yoder et al. 2004), and indicate that DiazaCon™ blocks
the conversion of desmosterol to cholesterol (Dietert and
Scallen 1969; Emmons et al. 1982). Experiments to test the
effect of DiazaCon™ on the Δ24-reductase enzyme, the enzyme
responsible for the conversion of desmosterol to cholesterol,
have yet to be conducted.
Plasma and faecal concentrations of testosterone, progesterone and oestradiol were evaluated using radioimmunoassay
in this study. However, the results are not reported here because
a component present in treated birds interfered with the assay.
Both desmosterol and DiazaCon™ interfered with the assay
used when tested. Because DiazaCon™ elevates desmosterol
concentrations this may be one possible source of cross-reactivity. In addition, DiazaCon™ metabolites may also cross-react
with the antibodies used in the radioimmunoassay kit.
DiazaCon™ can be associated with adverse health effects
and mortality (Sturtevant and Wentworth 1970; Yoder et al.
2004). In particular, DiazaCon™ is associated with myotonia
and has been used to experimentally induce myotonia for
research. Studies show desmosterol accumulates in muscle
membranes (Ramsey et al. 1978; Chalikian and Barchi 1982a;
Reddy et al. 1982), and erythrocyte membranes (Butterfield and
Watson 1977; Ashraf et al. 1984). Desmosterol may increase
membrane fluidity, thus impairing cell function (Ashraf et al.
1984). Changes in fluidity can affect membrane proteins and
enzymes, which in turn can affect cellular function (Langdon
et al. 1977; Chalikian and Barchi 1982b). Cataracts and
decreased renal concentrating capacity were observed in rats
(Peter et al. 1973), and changes were observed in adrenocortical
cells of Syrian hamsters (Yates et al. 1968). Toxicity likely is a
result of the cellular changes associated with changes in cell
membrane structure, with severity of effects being dependent on
the magnitude of the changes.
Mortality was associated with DiazaCon™ in pigeons
(Sturtevant and Wentworth 1970), quail (Powell 1966; Yoder
et al. 2004) and house sparrows (Sanders and Elder 1976).
Pigeons exhibited ruffled feathers, crouching, shivering and
increased liver weights, liver transaminase activity, and white
blood cell counts (Sturtevant and Wentworth 1970). Quail
exhibited weight loss, listlessness, difficulty breathing, and loss
of muscle control (Yoder et al. 2004).
In our study, mortality occurred in each of the gavage trials
but not in the nesting trial when birds were allowed to feed
freely. During the gavage studies, parakeets exhibited difficulty
breathing, generalised weakness and listlessness. Necropsies
performed at the University of Florida veterinary school in
Gainesville revealed no significant abnormalities. Although
toxicity may be greater when DiazaCon™ is given as a bolus
dose rather than being spread out over the day, the target dose in
the field should be less than 50 mg kg–1. Birds fed treated seed
at a target dose of 50 mg kg–1 consumed only enough seed to
receive a 17 mg kg–1 dose, and experienced no mortality, indicating that this was a safe dose.
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Mortality during the two gavage trials was predominantly
among males. In the salt form, DiazaCon™ is water soluble, but
once it has been absorbed in the gut it becomes water insoluble.
Because DiazaCon™ is lipophilic, females in a reproductive
state may be less susceptible to toxic effects. In reproductive
females most lipoproteins are targeted primarily to the egg,
whereas in males and non-breeding females lipoproteins are targeted to cells. Any lipophilic compounds ingested by breeding
females are therefore likely to end up sequestered in the egg
yolk rather than cells, potentially minimising harmful effects to
the female. The major component of egg yolk is very lowdensity lipoprotein, which is produced in the liver in response to
oestradiol stimulation. Some DiazaCon™ may be preferentially
deposited in the very low-density lipoprotein particles rather
than accumulating in the liver, leading to a lower risk of toxicity
in females during the breeding season. In non-laying birds,
DiazaCon™ will accumulate in the liver to a greater degree, and
thus has the potential for greater toxicity.
A DiazaCon™ dose approximately one-third less than the
target dose of 50 mg kg–1 effectively completely inhibited reproduction in the nesting study, although treated birds still laid
eggs. This was likely owing to the timing of treatment as egg
laying began shortly after treatment started. Treating birds
2–3 weeks earlier would likely cause complete cessation of egg
production.
DiazaCon™ is a promising contraceptive tool for monk
parakeets, and is associated with no ill health effects at a dose
less than 50 mg kg–1. In addition, it needs to be fed for only
5–10 days to affect reproduction for the length of a breeding
season. The effects are reversible, which allows management
flexibility. Used as part of an integrated management program,
DiazaCon™ could stem the rapid growth of monk parakeet
populations, thereby reducing the adverse impacts caused by
this exotic species.
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